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Introduction: Somatic mutations in the epidermal growth factor
receptor (EGFR) gene are associated with an increased response to
EGFR tyrosine kinase inhibitors (TKIs) such as gefitinib in patients
with non-small cell lung cancer (NSCLC). Although most NSCLC
patients with EGFR mutations benefit from EGFR-TKI treatment,
the efficacy of such treatment varies among individuals. Molecular
markers for prediction of EGFR-TKI treatment efficacy in EGFR
mutation-positive NSCLC have not been well defined.
Methods: The expression of mutant EGFR proteins was quantitated
by immunohistochemical analysis with mutation-specific antibodies
in tumor specimens from 47 NSCLC patients with postoperative
recurrent disease who harbored activating EGFR mutations. The
expression score was determined from both the staining intensity
and the proportion of tumor tissue expressing the mutant EGFR.
Results: The median progression-free survival after the start of
gefitinib treatment was significantly longer in patients with a high
score for mutant EGFR expression than in those with a low score
(12.2 versus 3.4 months, p  0.001), whereas no significant differ-
ence in median overall survival was apparent between the two
groups (24.9 versus 17.7 months, respectively, p  0.144). This
association between the expression score for mutant EGFR and
progression-free survival was apparent both in patients with dele-
tions in exon 19 of EGFR and in those with the L858R mutation in
exon 21.
Conclusions: Quantitative analysis of mutant EGFR expression by
immunohistochemical analysis with mutation-specific antibodies
may predict the efficacy of gefitinib treatment for EGFR mutation-
positive NSCLC.
Key Words: Activating EGFR mutation, Mutation-specific anti-
body, Immunohistochemistry, Non-small cell lung cancer, Gefitinib.
(J Thorac Oncol. 2012;7: 122–127)
Lung cancer is the leading cause of cancer death world-wide.1 Somatic mutations in the epidermal growth factor
receptor (EGFR) gene have been identified as a major deter-
minant of the clinical response to treatment with EGFR
tyrosine kinase inhibitors (TKIs) such as gefitinib and erlo-
tinib in individuals with non-small cell lung cancer (NSCLC).
Most of these mutations occur in exons 19 to 21, which
encode the tyrosine kinase domain of the receptor, with the
most common being deletions in exon 19 (such as delE746-
A750) and the L858R point mutation in exon 21. These
mutations are found more frequently in female patients, in
individuals who have never smoked, and in patients of East
Asian ethnicity.2–5 Prospective clinical trials of EGFR-TKI
treatment in NSCLC patients with EGFR mutations have
revealed radiographic response rates of 55 to 91%.6–17 Most
NSCLC patients with EGFR mutations thus benefit from
treatment with EGFR-TKIs. Nevertheless, the clinical effi-
cacy of EGFR-TKIs differs among such patients, and almost
all individuals eventually develop resistance to these drugs.
Recently, Yu et al18 prepared antibodies that specifically
recognize EGFRs that harbor the delE746-A750 or L858R
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mutations, allowing the development of a simple immuno-
histochemical method for identification of such mutations in
human tissue. We and others subsequently demonstrated the
potential value of these EGFR mutation-specific antibodies
for analysis of clinical tumor specimens.19–23 We have now
investigated whether the expression score for EGFR mutant
proteins is related to the efficacy of gefitinib treatment in
EGFR mutation-positive NSCLC.
PATIENTS AND METHODS
Patients and EGFR Mutation Analysis
In this retrospective study, we screened 110 consecu-
tive NSCLC patients with postoperative recurrent disease
who underwent surgery between 1995 and 2009. All the
patients received gefitinib (250 mg) orally once a day for
recurrent disease. EGFR mutations were identified either by
the PCR-Invader method (BML, Tokyo, Japan)24 in 40 pa-
tients or by the peptide nucleic acid-locked nucleic acid PCR
clamp method25 in 70 patients. Forty-seven patients were
found to harbor activating EGFR mutations (either exon 19
deletions or L858R in exon 21). Complete clinical informa-
tion and tissue blocks suitable for additional analysis were
available for all 47 individuals. A computed tomography scan
was performed for tumor assessment within 28 days of
initiation of treatment and was repeated after 2 to 3 months.
All responses were defined according to RECIST. Response
was confirmed at least 4 weeks (for a complete or partial
response) or 6 weeks (for stable disease) after it was first
documented. Progression-free survival (PFS) was calculated
from the date of initiation of gefitinib treatment either to the
date of disease progression or to the date of last contact. This
study conforms to the provisions of the Declaration of Hel-
sinki and was approved by the Institutional Review Board of
participating institutions.
Immunohistochemical Analysis of EGFR Mutant
Proteins in Clinical Samples from NSCLC
Patients
Paraffin-embedded tumor tissue was sectioned at a
thickness of 4 m, and the sections were mounted on glass
slides and then incubated with mutation-specific antibodies to
EGFR that specifically recognize the delE746-A750 mutation
in exon 19 (clone 6B6; Cell Signaling Technology) or the
L858R mutation in exon 21 (clone 43B2; Cell Signaling
Technology) for immunohistochemical analysis with the use
of a Dako autostainer (Dako Cytomation).18 The proportion
of tumor cells found to express an EGFR mutant (proportion
score) was assessed according to the following scale: 0, none
(0%); 1, 1 to 10%; 2, 11 to 30%; 3, 31 to 50%; 4, 51 to 70%;
and 5, 71 to 100% of tumor cells. The intensity of staining
(intensity score) was evaluated according to the following
scale: 0, no staining; 1, weak staining; 2, moderate staining;
and 3, strong staining in10% of cancer cells. As previously
described,26,27 the proportion score and intensity score were
added to yield a total expression score ranging from 0 to 8.
We classified expression scores of 0 to 3 as low expression
and those of 4 to 8 as high expression for exon 19 deletions
and expression scores of 0 to 6 as low expression and those
of 7 or 8 as high expression for the L858R mutation, given
that the corresponding median scores for the two types of
mutation were 4 and 7, respectively. All immunohistochem-
ical analysis was evaluated by two experienced observers
(A.K. and M.K.) who were unaware of the conditions of the
patients.
Statistical Analysis
We used Fisher’s exact test to evaluate the significance
of relations between the expression score for EGFR mutants
and other patient characteristics. Survival curves for both PFS
and OS were estimated by the Kaplan-Meier method, and the
difference between the curves for patients with a high or low
expression score for EGFR mutants was evaluated by the
log-rank test. The Cox proportional hazards model was ap-
plied to examine whether the expression score for mutant
EGFR proteins was associated with PFS or OS even after
adjustment for other prognostic factors. All tests were two
sided, and a p value of 0.05 was considered statistically
significant. Statistical analysis was performed with R version
2.90 and SAS version 9.2 software (SAS Institute, Cary, NC).
RESULTS
Patient Characteristics
The clinical characteristics of the 47 patients are shown
in Table 1 (also see Supplemental Table, Supplemental Dig-
ital Content 1, http://links.lww.com/JTO/A151). Thirty-five
(74%) patients were female and 36 (77%) were never-smok-
ers, with the median age of all patients being 65 years (range,
46–82 years). Forty-five (96%) patients had adenocarci-
noma, 31 (66%) had a good performance status (Eastern
Cooperative Oncology Group 0), and 15 patients (32%)
received EGFR-TKI treatment as first-line chemotherapy.
With regard to the type of EGFR mutation, 27 patients had
deletions in exon 19, and 20 patients had the L858R missense
mutation in exon 21.
Immunohistochemical Analysis of Activating
EGFR Mutations in NSCLC Patients
Representative images for immunohistochemical stain-
ing of tumor specimens with antibodies specific for the two
different types of EGFR mutation are shown in Figure 1.
According to the protocol definition, the expression of the
mutant EGFR proteins was evaluated on the basis of both the
proportion of stained cells and staining intensity. There was a
strong correlation between the proportion score and the in-
tensity score (Spearman p  0.760). We determined the
expression score for the mutant proteins as the sum of
the proportion score and the intensity score and divided the
patients in the study into two groups according to the expres-
sion score. Twenty-eight and 19 patients were thus found to
have high and low expression scores, respectively. We ex-
amined the possible relation between the expression score of
the EGFR mutants and various clinical characteristics, but no
significant association was found with age, sex, tumor histol-
ogy, smoking status, or performance status (Table 2).
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Relation of Expression Score for EGFR Mutants
to Survival
At the time of analysis, the median follow-up time was
15.0 months (range, 1.5–57.9 months). The median PFS
was 6.7 months (range, 0.7–36.0 months), and the median OS
was 15.0 months (range, 1.5–57.9 months). At this time, three
patients were still receiving gefitinib treatment. The median
duration of gefitinib treatment in patients with a high or low
expression score was 12.2 (range, 0.3–36.0) and 3.4 (range,
0.7–17.2) months, respectively. Kaplan-Meier analysis of
PFS and OS after the start of gefitinib treatment is shown in
Figure 2. The log-rank test revealed that gefitinib treatment
resulted in a significantly longer PFS in patients with a high
expression score for EGFR mutants than in those with a low
expression score (median of 12.2 versus 3.4 months, p 
0.001; Figure 2A), whereas there was no significant differ-
ence in OS between the two groups of patients (median, 24.9
versus 17.7 months, respectively, p 0.144; Figure 2B). This
difference in PFS between patients with high and low expres-
sion scores was apparent for both types of EGFR mutation
(Figure 2C, D). Univariate analysis revealed that a high
expression score for EGFR mutants (p  0.001) was signif-
icantly associated with PFS and that performance status (p 
0.034) was significantly associated with OS (Table 3). None
of the other factors examined was significantly associated
with either PFS or OS. Finally, Cox regression analysis
revealed that expression score for the EGFR mutants was
significantly associated with PFS (hazard ratio, 0.265; 95%
confidence interval, 0.132–0.531; p  0.001) independently
of performance status (Table 4). The relation between expres-
sion score for EGFR mutants and OS was close to achieving
statistical significance after adjustment for performance status
(hazard ratio, 0.503; 95% confidence interval, 0.231–1.093;
p  0.083).
Poststudy Treatment
Nine (32%) of the 28 patients who had a high expres-
sion score for EGFR mutants received subsequent treatment,
whereas 8 (42%) of the 19 patients with a low expression
score received such treatment. There was thus no significant
difference in poststudy treatment between the two groups (2,
p  0.4866).
DISCUSSION
With the use of mutation-specific antibodies, we have
performed immunohistochemical analysis of the expression
of mutant EGFR proteins in tumor specimens obtained from
relapsed NSCLC patients with EGFR mutations. We found
that the expression score for mutant EGFR proteins, as
determined by quantitation of both staining intensity and the
proportion of tumor cells expressing the mutant proteins, was
significantly associated with PFS after the onset of gefitinib
treatment. We previously showed that EGFR mutation was
significantly associated with EGFR amplification in NSCLC
cell lines and that the mutant EGFR proteins in such cells
with both of these types of EGFR alteration were activated
constitutively, resulting in an increased sensitivity to EGFR-
TKIs.28 These findings suggested that EGFR mutant alleles
are amplified selectively and that increased expression of the
mutant EGFR proteins confers susceptibility to EGFR-
TKIs.28,29 In this study, we found that a high staining intensity
for mutant EGFR proteins was associated with a longer PFS
in EGFR mutation-positive NSCLC patients treated with
gefitinib (see Supplemental Figure, Supplemental Digital
Content 2, http://links.lww.com/JTO/A151). In addition to
staining intensity, we measured the proportion of tumor tissue
in which the mutant EGFR protein was expressed. Many
types of cancer have been found to manifest tissue heteroge-
neity with regard to the detection of tumor suppressor genes
or oncogenes.30,31 Previous studies have also suggested that
such heterogeneity is also the case for EGFR mutations in
NSCLC cell lines and tumor tissue.24,32 Consistent with these
findings, we have now shown that mutant EGFR protein
detected with mutation-specific antibodies was expressed
heterogeneously in individual tumors. Although intratumoral
heterogeneity for EGFR mutations may explain the variable
clinical efficacy of EGFR-TKIs in EGFR mutation-positive
NSCLC patients, this issue has not previously been clinically
addressed. We have now found that a high proportion score
TABLE 1. Patient Characteristics
Characteristic
Age (yr)
Median 65
Range 46–82
Sex
Male 12
Female 35
Histology
Adenocarcinoma 45
Squamous cell carcinoma 1
Adenosquamous cell carcinoma 1
Smoking status
Never-smoker 36
Smoker 11
Performance status
0 31
1 9
2 7
Gefitinib
First line 15
Second line 20
Third line 11
Fourth line 1
EGFR mutation status
L858R 20
Exon19 deletions 27
Metastases
Lung 30
Brain 20
Bone 16
Liver 5
Lymph node 2
Adrenal 1
Skin 1
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for mutant EGFR proteins was associated with a longer PFS
in EGFR mutation-positive NSCLC patients treated with
gefitinib (see Supplemental Figure, Supplemental Digital
Content 2, http://links.lww.com/JTO/A151). Together, these
findings suggest that the combination of the proportion score
and intensity score for EGFR mutants might prove useful for
predicting the efficacy of EGFR-TKIs in NSCLC patients
harboring EGFR mutations.
The efficacy of EGFR-TKIs varies among EGFR mu-
tation-positive NSCLC patients, but no clear candidate for a
molecular marker able to predict treatment response in such
patients has been identified. The T790M mutation of EGFR
has been associated with acquired resistance to EGFR-TKIs
in EGFR mutation-positive NSCLC patients, and this muta-
tion was recently shown to be present in 35% of such patients
before treatment with gefitinib and to be associated with de
novo resistance to this drug.33,34 A low expression level of the
endogenous NF-B inhibitor IB was recently shown to be
predictive of a poor clinical outcome in a cohort of erlotinib-
treated NSCLC patients harboring an activating EGFR mu-
tation but lacking evidence of the T790M mutation.35 In this
study, we have demonstrated that quantitative analysis of
EGFR mutant expression in tumor tissue predicts the efficacy
of EGFR-TKIs in NSCLC patients harboring EGFR muta-
tions. Several highly sensitive methods for the detection of
EGFR mutations have been described which can detect such
mutations in specimens containing only a low percentage
of mutation-positive cancer cells. Although these methods
are useful for diagnosis of EGFR mutation-positive cancer,
they are qualitative rather than quantitative.24,25 One ad-
vantage of immunohistochemical diagnosis is that it pro-
vides a quantitative measurement of the expression level of
the mutant protein in the cancer cells from individual
patients. A potential drawback of this technique is that the
sensitivity of the antibodies that detect exon 19 deletions is
slightly inferior to that of the antibodies specific for the
L858R mutant.18–23 Consistent with this difference, we found
that the sensitivity for the immunohistochemical detection of
exon 19 deletions or the L858R mutation was 78 and 100%,
respectively. These results thus indicate that not all EGFR
FIGURE 1. Immunohistochemical staining of NSCLC adenocarcinoma specimens with antibodies specific for delE746-A750
or L858R mutant forms of EGFR. Representative staining patterns for each of the four intensity levels are shown (original mag-
nification, 400).
TABLE 2. Relation Between Expression Score for EGFR
Mutants and Various Patient Characteristics
Characteristic n
Expression
Score
paLow High
Age (yr)
High (65) 26 12 14 0.550
Low (65) 21 7 14
Sex
Male 12 6 6 0.505
Female 35 13 22
Histology
Adenocarcinoma 45 18 27 1.000
Squamous  adenosquamous 2 1 1
Smoking status
Never-smoker 36 14 22 0.736
Smoker 11 5 6
Performance status
0 31 14 17 0.531
1 or 2 16 5 11
Response rate
PR or SD 38 12 26 0.021
PD 9 7 2
a Determined by Fisher exact test.
PR, partial response; SD, stable disease; PD, progressive disease.
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mutant protein in cancer cells could be detected by immunohis-
tochemical analysis.
The PFS benefit of gefitinib treatment in patients with
a high expression score for mutant EGFR relative to those
with a low expression score did not translate into an OS
benefit. One explanation for this finding is that the sample
size was too small to detect a clinically significant difference
in OS. In addition, the data for OS were premature, with 40%
of patients still being alive when censored. Although the
frequency of EGFR mutations is only 20 to 30% in East
Asians and 10% in Caucasians, efforts are ongoing to
confirm our findings in larger cohorts.
In conclusion, we found that a high expression score for
mutant EGFR protein is associated with a longer PFS in
EGFR mutation-positive NSCLC patients treated with ge-
fitinib. Our clinical findings demonstrate that quantitative
analysis of EGFR mutant expression may predict the efficacy
of EGFR-TKIs for treatment of EGFR mutation-positive
NSCLC. Further study is warranted to clarify the clinical
utility of immunohistochemical analysis for EGFR mutant
proteins in determination of the optimal treatment for EGFR
mutation-positive NSCLC.
FIGURE 2. Kaplan-Meier survival
curves according to expression
score for EGFR mutants. PFS (A) and
OS (B) for patients with high or low
expression scores for either type of
EGFR mutant. PFS for patients with
high or low expression scores for
exon 19 deletion (C) or L858R (D)
mutant forms of EGFR.
TABLE 3. Factors Associated with PFS and OS
Factor n
Median
PFS (mo) pa
Median
OS (mo) pa
Age (yr)
High (65) 26 7.4 0.872 21.6 0.711
Low (65) 21 5.4 18.2
Sex
Male 12 3.4 0.857 10.3 0.537
Female 35 8.1 25.5
Histology
Adenocarcinoma 45 6.5 0.170 23.7 0.941
Squamous 
adenosquamous
2 4.2 13.5
Smoking
Never-smoker 36 7.4 0.640 25.5 0.339
Smoker 11 3.1 11.2
Performance status
0 31 8.3 0.143 35.3 0.034
1 or 2 16 5.6 12.5
EGFR-mutant
expression score
Low 19 3.4 0.001 17.7 0.144
High 28 12.2 24.9
a Univariate analysis by log-rank test.
PFS, progression-free survival.
TABLE 4. Multivariate Analysis of PFS and OS
Parameter HR (95% CI) pa
PFS EGFR-mutant expression
score (high vs. low)
0.265 (0.132–0.531) 0.001
Performance status
(0 vs. 1 or 2)
1.720 (0.901–3.283) 0.100
OS EGFR-mutant expression
score (high vs. low)
0.503 (0.231–1.093) 0.083
Performance status
(0 vs. 1 or 2)
2.546 (1.137–5.702) 0.028
a Multivariate analysis by Cox proportional hazards model.
PFS, progression-free survival; HR, hazard ratio; CI, confidence interval.
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